Publications and Presentations

Check out our publications and poster presentations.

December 2017

Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer

San Antonio Breast Cancer Symposium

November 2017

CX-839-004: A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer-Oral Presentation CX-839-004: A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer

Society for Immunotherapy of Cancer

June 2017

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors

American Society of Clinical Oncology – 2017

March 2017

CB-839, a Selective Glutaminase Inhibitor, has Anti-Tumor Activity in Renal Cell Carcinoma and Synergizes with Cabozantinib and Everolimus

Keystone Symposia on Tumor Metabolism

January 2017

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer

Cell Reports

Our Pipeline

We are focused on novel treatments for
cancer and other life-threatening diseases.

View Our Pipeline